Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT01862718 | Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms | terminated | Phase 1 | 5 | National Institutes of Health Clinical Center (CC)NIH |
| 1 |
| Aug 15, 2022 |
| clinicaltrials |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma | terminated | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT02446925 | Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study | terminated | N/A | 8 | Wright State UniversityOTHER | 0 | Jul 28, 2022 | clinicaltrials |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Kathy MillerOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT00746590 | Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | terminated | Phase 2 | 1 | BTG International Inc.OTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT03402607 | Trial Comparing PLA to HIGRT (PROVE-HCC)(PROVE-HCC) | terminated | N/A | 12 | Duke UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT01402908 | A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection(PATRON) | terminated | Phase 3 | 520 | Cellxpert Biotechnology Corp.INDUSTRY | 4 | Jun 23, 2022 | clinicaltrials |
| NCT03956940 | Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib(HELP) | terminated | N/A | 18 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04187937 | Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections | terminated | N/A | 1 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 7 | SignalRX Pharmaceuticals, Inc.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT02866344 | Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases | terminated | N/A | 1 | Wake Forest University Health SciencesOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 140 | Polaris GroupINDUSTRY | 6 | Apr 25, 2022 | clinicaltrials |
| NCT02704130 | TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma | terminated | N/A | 8 | Wake Forest University Health SciencesOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT03396705 | Liver Regeneration | terminated | — | 2 | University Health Network, TorontoOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT03979547 | EXALT: EXercise Attenuates Liver Tumors Trial(EXALT) | terminated | N/A | 3 | Milton S. Hershey Medical CenterOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT04653389 | Perioperative Therapy for Hepatocellular Carcinoma | terminated | Phase 2 | 10 | Zhejiang UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04476329 | Optimization for Regorafenib in HCC(ReDos HCC) | terminated | Phase 2 | 7 | SC Liver Research Consortium, LLCOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer(HiQuality) | terminated | Phase 3 | 235 | Merit Medical Systems, Inc.INDUSTRY | 5 | Nov 30, 2021 | clinicaltrials |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma(DESPARTH) | terminated | Phase 1 | 2 | University Hospital, GhentOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT01141478 | Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria(HCC) | terminated | N/A | 8 | Loma Linda UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT01098422 | A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver | terminated | N/A | 10 | Tony Reid, M.D., Ph.D.OTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT03203304 | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | terminated | Phase 1 | 14 | University of ChicagoOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT01032850 | Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | terminated | Phase 2 | 15 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02893982 | High Dose Rate Brachyablation of Primary Liver Lesions | terminated | Phase 1 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT02721056 | NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers | terminated | Phase 1 / Phase 2 | 23 | NanobiotixINDUSTRY | 1 | May 10, 2021 | clinicaltrials |
| NCT03608878 | Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype | terminated | Phase 2 | 5 | Chang Gung Memorial HospitalOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT04264754 | Characterization of Methylation Patterns in Hepatocellular Carcinoma | terminated | — | 120 | Nucleix Ltd.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT01887717 | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein(YES-P) | terminated | Phase 3 | 36 | Boston Scientific CorporationINDUSTRY | 6 | Apr 21, 2021 | clinicaltrials |
| NCT03516695 | RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry(READ90Y) | terminated | — | 95 | Boston Scientific CorporationINDUSTRY | 2 | Apr 21, 2021 | clinicaltrials |
| NCT03137706 | Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer | terminated | — | 8 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03563274 | QuiremSpheres Observational Study(Hope166) | terminated | — | 20 | Terumo Europe N.V.INDUSTRY | 2 | Mar 29, 2021 | clinicaltrials |
| NCT03303469 | Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging | terminated | Phase 2 | 3 | University of Alabama at BirminghamOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02460991 | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma(SOLACE) | terminated | Phase 3 | 2 | Boston Scientific CorporationINDUSTRY | 1 | Feb 12, 2021 | clinicaltrials |
| NCT03008512 | A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib | terminated | Phase 2 | 5 | Gachon University Gil Medical CenterOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02524119 | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma(LEE001) | terminated | Phase 2 | 5 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02470533 | Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma(TRENDY) | terminated | Phase 2 | 100 | Erasmus Medical CenterOTHER | 3 | Jan 27, 2021 | clinicaltrials |
| NCT03219372 | Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence | terminated | Phase 2 | 1 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04702230 | Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization | terminated | — | 32 | University of ZurichOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT00823290 | Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 | 2 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT00503867 | SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | terminated | N/A | 10 | Sirtex MedicalINDUSTRY | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT02966223 | A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver | terminated | N/A | 20 | Indiana UniversityOTHER | 1 | Sep 25, 2020 | clinicaltrials |
| NCT03203837 | Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | terminated | — | 4 | Northwestern UniversityOTHER | 1 | Sep 9, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 18, 2022source: clinicaltrials